STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (OMX: ORX), the Swedish pharmaceutical company, and ProStrakan Group plc, the Scottish-based international specialty pharmaceutical company, have extended their existing European licensing agreement for Rapinyl™ (Abstral®), for breakthrough cancer pain, to include North America. This change of partner in North America follows the decision made by Endo Pharmaceuticals Holdings Inc. today following its own internal strategy changes to return all rights for Rapinyl™ (Abstral®) to Orexo. Endo has invested approximately $40 million in the development of Rapinyl™, and Orexo has received an additional $26.9 million in licensing payments. Endo will finalize and finance the current phase III studies of Rapinyl™ expected to end in December 2008.
